Description:Tepotinib is a small molecule inhibitor primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets the MET receptor tyrosine kinase, which plays a crucial role in cell signaling pathways that regulate cell growth and survival. Tepotinib is particularly effective against tumors that exhibit MET exon 14 skipping mutations, leading to aberrant MET activation. The compound is characterized by its ability to selectively inhibit the MET signaling pathway, thereby reducing tumor proliferation and promoting apoptosis in cancer cells. Tepotinib is administered orally and has been studied for its pharmacokinetics, safety profile, and efficacy in clinical trials. Common side effects may include fatigue, nausea, and liver enzyme elevations. As a targeted therapy, Tepotinib represents a significant advancement in personalized medicine, offering a treatment option for patients with specific molecular profiles in their tumors. Its development underscores the importance of molecular diagnostics in oncology, allowing for more tailored therapeutic approaches.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyr…](https://static.cymitquimica.com/products/IN/thumb/DA0039KZ.jpg)
